Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
$42.43
-$0.78(-1.91%)
At close: 4:00 PM EST
$42.43
-$0.78(-1.91%)
Day’s Range― - ―
52-Week Range$26.74 - $46.60
Previous CloseN/A
Volume41.45K
Average Volume (3M)895.56K
Market Cap
$3.20B
Enterprise Value$3.18B
Total Cash (Recent Filing)$462.27M
Total Debt (Recent Filing)$8.33M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Feb 26, 2026EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding77,275,000
10 Day Avg. Volume695,153
30 Day Avg. Volume895,558
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)4.04
Price to Sales (P/S)0.00
P/FCF Ratio-16.55
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue424.65
Enterprise Value/Gross Profit-45.38
Enterprise Value/Ebitda-9.59
Forecast
1Y Price Target
$54.78Price Target Upside29.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutA positive phase three readout for azetukalner may confirm a favorable risk–benefit profile, support an NDA submission, and materially lift investor confidence in the stock.
Commercial Differentiation And PositioningOnce‑daily dosing, no complex titration, limited drug–drug interaction requirements, and an evolving commercial team could help azetukalner achieve stronger adoption than many recent branded antiseizure launches.
Durable Long-term EfficacyLong‑term open‑label data showing substantial and durable seizure reductions in highly treatment‑resistant patients reinforces confidence in azetukalner's therapeutic value and commercial potential.
Bears Say
Cash Burn And FinancingNegative cash flow from operations may necessitate additional financing, creating dilution risk and potential downward pressure on the stock if capital access is constrained.
Commercial Adoption RiskPrecedent of slow launches for newly branded antiseizure drugs raises the risk that azetukalner's market uptake may be slower than clinical data alone would suggest.
Development Safety ConcernsHeart‑safety signals in a lead pain program elevate development risk and could require additional studies or modifications that divert resources and affect valuation.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $26.74 and its highest was $46.60 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $3.20B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Feb 26, 2026 which is in 14 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Nov 03, 2025. The company reported -$1.15 earnings per share for the quarter, beating the consensus estimate of -$1.152 by $0.002.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.19.
How many shares outstanding does Xenon have?
Xenon has 77,275,000 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$1.15 in its last earnings report, beating expectations of -$1.152. Following the earnings report the stock price went down -4.937%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.78 (29.11% Upside)
$54.78 (29.11% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 154.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.21%
12-Months-Change
Fundamentals
Return on Equity
-45.14%
Trailing 12-Months
Asset Growth
-27.28%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Xenon's late-stage and early-stage clinical programs, particularly for azetukalner in epilepsy and neuropsychiatric disorders. Financially, the company is well-positioned to support its operations and pipeline development. While challenges exist, such as increased competition and screening hurdles, the positive advancements and robust financial health contribute to an overall optimistic outlook.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$54.78
▲(29.11% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.10% Insiders
31.67% Mutual Funds
0.25% Other Institutional Investors
61.80% Public Companies and
Individual Investors